64.58
-1.34 (-2.03%)
-1.34 (-2.03%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NVO | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 65.92 | 0.00 | 0.00 | 0.00 | 65.92 | 09:08:53 |
| Stock Trades | Traded Volume | Average Volume | 52 Week Range |
|---|---|---|---|
| 24 | 2,669 | 1,360,995 | 47.15 - 68.715 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:08:36 | formt | 100 | $ 64.58 | USD |
Novo Nordisk Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 153.78B | 2.33B | 2.33B | $ - | $ - | 2.46 | 25.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 3.43M | $ - | 235.87% | - | - |
Novo Nordisk News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 64.74 | 66.68 | 64.50 | 65.85 | 1,308,978 | 1.18 | 1.82% |
| 1 Month | 64.60 | 68.715 | 63.8601 | 65.93 | 1,473,217 | 1.32 | 2.04% |
| 3 Months | 59.41 | 68.715 | 58.66 | 64.03 | 1,569,346 | 6.51 | 10.96% |
| 6 Months | 57.00 | 68.715 | 49.24 | 60.73 | 1,872,181 | 8.92 | 15.65% |
| 1 Year | 50.33 | 68.715 | 47.15 | 57.33 | 1,698,698 | 15.59 | 30.98% |
| 3 Years | 41.71 | 68.715 | 41.03 | 51.59 | 1,561,138 | 24.21 | 58.04% |
| 5 Years | 54.32 | 68.715 | 30.89 | 48.15 | 1,785,066 | 11.60 | 21.35% |
Novo Nordisk Description
| With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
